Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | HBB | P68871 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.48 |
| ▸ | UMPS | P11172 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15248806 | 1.00 | LMNA (0.56) | LMNATP53HBBSMN1; SMN2SIRT2 | |
| SCHEMBL14928421 | 1.00 | LMNA (0.56) | LMNATP53HBBSMN1; SMN2SIRT2 | |
| SCHEMBL14946175 | 0.92 | ENTPD1 (0.53) | LMNATP53HBBSMN1; SMN2ENTPD1 | |
| SCHEMBL15836214 | 0.88 | LMNA (0.49) | LMNATP53HBBSMN1; SMN2SIRT2 | |
| SCHEMBL16543524 | 0.87 | SMN1; SMN2 (0.75) | LMNATP53HBBSMN1; SMN2SIRT2 | |
| SCHEMBL15305337 | 0.87 | SMN1; SMN2 (0.75) | LMNATP53HBBSMN1; SMN2SIRT2 | |
| SCHEMBL29810834 | 0.87 | SMN1; SMN2 (0.75) | LMNATP53HBBSMN1; SMN2SIRT2 | |
| SCHEMBL15249229 | 0.84 | SMN1; SMN2 (0.58) | LMNATP53HBBSMN1; SMN2SIRT2 | |
| SCHEMBL15746177 | 0.82 | RNASEL (0.54) | LMNATP53HBBSMN1; SMN2SIRT2 | |
| SCHEMBL17210941 | 0.81 | P2RY2 (0.49) | ENTPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9149506-B2 | Modified polynucleotides encoding septin-4 | MODERNA THERAPEUTICS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | MODERNA THERAPEUTICS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | modeRNA Therapeutics (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140141067-A1 | MODIFIED POLYNUCLEOTIDES ENCODING SEPTIN-4 | SEPTIN7, SEPTIN9, SEPTIN8 | LMNA 673/4885TP53 168/4885HBB 3127/4885 |
| US-20130165504-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | LMNA 281/4885TP53 782/4885HBB 3803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.